Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

Similar articles for PubMed (Select 23417334)

1.

Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.

Yoon H, Cho HY, Yoo HD, Kim SM, Lee YB.

AAPS J. 2013 Apr;15(2):571-80. doi: 10.1208/s12248-013-9460-z. Epub 2013 Feb 16.

2.

Clinical pharmacokinetics of metformin.

Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM.

Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000. Review.

PMID:
21241070
3.

A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin.

Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P, Beck-Nielsen H, Brøsen K.

Pharmacogenet Genomics. 2013 Oct;23(10):526-34. doi: 10.1097/FPC.0b013e328364a57d.

PMID:
23873119
4.

Genetic variants of the organic cation transporter 2 influence the disposition of metformin.

Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, Shin JG.

Clin Pharmacol Ther. 2008 Nov;84(5):559-62. doi: 10.1038/clpt.2008.61. Epub 2008 Apr 9.

PMID:
18401339
5.

Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.

Grün B, Kiessling MK, Burhenne J, Riedel KD, Weiss J, Rauch G, Haefeli WE, Czock D.

Br J Clin Pharmacol. 2013 Nov;76(5):787-96. doi: 10.1111/bcp.12079.

6.

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolić I, Koepsell H, Brockmöller J.

Clin Pharmacol Ther. 2009 Sep;86(3):299-306. doi: 10.1038/clpt.2009.92. Epub 2009 Jun 17.

PMID:
19536068
7.

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.

Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM.

Clin Pharmacol Ther. 2008 Feb;83(2):273-80. Epub 2007 Jul 4.

8.

OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine.

Wang ZJ, Yin OQ, Tomlinson B, Chow MS.

Pharmacogenet Genomics. 2008 Jul;18(7):637-45. doi: 10.1097/FPC.0b013e328302cd41.

PMID:
18551044
9.

Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function.

Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC, Timmins P, Graham GG, Furlong TJ, Greenfield JR, Williams KM, Day RO.

Clin Pharmacokinet. 2013 May;52(5):373-84. doi: 10.1007/s40262-013-0046-9.

PMID:
23475568
10.

Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition.

Song IS, Lee do Y, Shin MH, Kim H, Ahn YG, Park I, Kim KH, Kind T, Shin JG, Fiehn O, Liu KH.

PLoS One. 2012;7(5):e36637. doi: 10.1371/journal.pone.0036637. Epub 2012 May 8.

11.

Disposition of metformin: variability due to polymorphisms of organic cation transporters.

Zolk O.

Ann Med. 2012 Mar;44(2):119-29. doi: 10.3109/07853890.2010.549144. Epub 2011 Mar 3. Review.

PMID:
21366511
12.

Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin.

Nakamichi N, Shima H, Asano S, Ishimoto T, Sugiura T, Matsubara K, Kusuhara H, Sugiyama Y, Sai Y, Miyamoto K, Tsuji A, Kato Y.

J Pharm Sci. 2013 Sep;102(9):3407-17. doi: 10.1002/jps.23595. Epub 2013 May 10.

PMID:
23666872
13.

The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.

Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, Ramirez AH, Roden DM, Wilke RA, McCarty CA, Davis RL, Brett CM, Giacomini KM.

Clin Pharmacol Ther. 2013 Feb;93(2):186-94. doi: 10.1038/clpt.2012.210. Epub 2012 Oct 17.

14.

Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome.

Gambineri A, Tomassoni F, Gasparini DI, Di Rocco A, Mantovani V, Pagotto U, Altieri P, Sanna S, Fulghesu AM, Pasquali R.

J Clin Endocrinol Metab. 2010 Oct;95(10):E204-8. doi: 10.1210/jc.2010-0145. Epub 2010 Jul 21.

PMID:
20660041
15.

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.

Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM.

Pharmacogenet Genomics. 2009 Jul;19(7):497-504. doi: 10.1097/FPC.0b013e32832cc7e9.

16.

Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.

Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, Ieiri I.

J Hum Genet. 2007;52(2):117-22. Epub 2006 Nov 17.

PMID:
17111267
17.

Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics.

Chung JY, Cho SK, Kim TH, Kim KH, Jang GH, Kim CO, Park EM, Cho JY, Jang IJ, Choi JH.

Pharmacogenet Genomics. 2013 Jul;23(7):365-73. doi: 10.1097/FPC.0b013e3283622037.

PMID:
23652408
18.

Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.

Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2012 Jun;40(6):1170-7. doi: 10.1124/dmd.112.044875. Epub 2012 Mar 9.

19.

The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.

Ding Y, Jia Y, Song Y, Lu C, Li Y, Chen M, Wang M, Wen A.

Eur J Clin Pharmacol. 2014 Feb;70(2):141-6. doi: 10.1007/s00228-013-1604-7. Epub 2013 Oct 30.

PMID:
24170325
20.

Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.

Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, Park MS, Chung JY.

Clin Pharmacol Ther. 2011 Mar;89(3):416-21. doi: 10.1038/clpt.2010.266. Epub 2011 Jan 26.

PMID:
21270793
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk